SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-024841
Filing Date
2024-03-21
Accepted
2024-03-21 17:14:29
Documents
7
Period of Report
2024-03-21

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0202255-6k_nlspharma.htm 6-K 20752
2 FORM OF COMMON WARRANT ea020225501ex4-1_nlspharma.htm EX-4.1 88427
3 FORM OF PLACEMENT AGENT WARRANT ea020225501ex4-2_nlspharma.htm EX-4.2 89476
4 OPINION OF WENGER VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD ea020225501ex5-1_nlspharma.htm EX-5.1 26625
5 FORM OF SECURITIES PURCHASE AGREEMENT, DATED MARCH 20, 2024, BY AND BETWEEN NLS ea020225501ex10-1_nlspharma.htm EX-10.1 263384
6 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES $1.75 MILLION REGISTERED DIRE ea020225501ex99-1_nlspharma.htm EX-99.1 11704
7 GRAPHIC ex5-1_001.jpg GRAPHIC 3283
  Complete submission text file 0001213900-24-024841.txt   506072
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 24772309
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)